Assessing response to treatment using imaging with PET/MRI in advanced renal cancer

Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI): The REMAP study

Registry ID

ISRCTN12114913

Source registry

ISRCTN

Status

No longer recruiting

Study type

INTERVENTIONAL

Sponsor

King's College London

Enrollment

38

Start date

2016-12-01

Completion date

2023-02-01

Last update

2026-08-17

Conditions

• Cancer
• Malignant neoplasm of kidney, except renal pelvis

Summary

Renal cell carcinoma

Detailed description

Participants with metastatic renal cell cancer will undergo FDG PET/MRI scans at baseline, 12 and 24 weeks following the start of their standard treatment and results compared to the routine clinical CT scans at these time-points. Each PET/MRI will take approximately one hour. The imaging intervention is over 24 weeks and the imaging follow up period extends to the 36 week clinical CT scan. Subsequent consensus panel assessment of clinical and all imaging data up to 36-weeks will confirm disease status.

Interventions

• OTHER: Participants with metastatic renal cell cancer will undergo FDG PET/MRI scans at baseline, 12 and 24 weeks following the start of their standard treatment and results compared to the routine clinical CT scans at these time-points. Each PET/MRI will take approximately one hour. The imaging intervention is over 24 weeks and the imaging follow up period extends to the 36 week clinical CT scan. Subsequent consensus panel assessment of clinical and all imaging data up to 36-weeks will confirm disease

Inclusion criteria

1. Adult patients (male or female > 18 years old) with metastatic renal cell carcinoma 2. Metastases with ≥1 measurable sites, ≥2cm, planned for targeted therapy 3. ECOG performance status 0-2

Exclusion criteria

1. Contraindications to contrast-enhanced MRI or CT or FDG PET including renal impairment eGFR <50 2. Estimated prognosis < 12 weeks 3. ECOG performance status > 2 4. Previous radiotherapy

Locations

• , , England
• , , United Kingdom

Related clinical trials

• Testing whether a fast MRI scan can detect breast cancers which were not detected on mammograms, in women with average breast density
• IBIS-II-O: Observational long-term follow up study of participants from the IBIS-II DCIS and Prevention clinical trials of drugs for breast cancer prevention
• Testing tumour genetics in patients with cancers resistant to standard-of-care therapy
• A clinical trial to investigate if proton beam therapy with chemotherapy given before surgery for patients with oesophageal cancer that has spread to the surrounding tissues, significantly reduces the severe side effects to the heart and lungs and allows immunotherapy to be started sooner after surgery when compared with standard radiotherapy and chemotherapy before surgery, and whether this delivers value to the NHS and patients
• CRISTAL-APC - a trial of chemokine receptor inhibition for patients with pancreatic cancer
• Is complete decongestive therapy a feasible and acceptable intervention for patients with lymphoedema following treatment for head and neck cancer?

View on source registry